Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)
Anna Binda,1 Carmen Murano,1 Ilaria Rivolta2 1School of Medicine and Surgery, University of Milano-Bicocca, Monza (MB) 20900, Italy; 2School of Medicine and Surgery, Nanomedicine Center NANOMIB, NeuroMI Milan Center for Neuroscience, University of Milano-Bicocca, Monza (MB) 20900, ItalyCorrespondenc...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2020
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/d1505d3c156e416d9cba6fd283c5f4cb |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Anna Binda,1 Carmen Murano,1 Ilaria Rivolta2 1School of Medicine and Surgery, University of Milano-Bicocca, Monza (MB) 20900, Italy; 2School of Medicine and Surgery, Nanomedicine Center NANOMIB, NeuroMI Milan Center for Neuroscience, University of Milano-Bicocca, Monza (MB) 20900, ItalyCorrespondence: Ilaria Rivolta Tel +39 2 64488319Email ilaria.rivolta@unimib.itAbstract: The field of nanomedicine is constantly expanding. Since the first work dated in 1999, almost 28 thousand articles have been published, and more and more are published every year: just think that only in the last five years 20,855 have come out (source PUBMED) including original research and reviews. The goal of this review is to present the current knowledge about nanomedicine in Alzheimer’s disease, a widespread neurodegenerative disorder in the over 60 population that deeply affects memory and cognition. Thus, after a brief introduction on the pathology and on the state-of-the-art research for NPs passing the BBB, special attention is placed to new targets that can enter the interest of nanoparticle designers and to new promising therapies. The authors performed a literature review limited to the last three years (2017– 2020) of available studies with the intention to present only novel formulations or approaches where at least in vitro studies have been performed. This choice was made because, while limiting the sector to nanotechnology applied to Alzheimer, an organic census of all the relevant news is difficult to obtain.Keywords: Alzheimer’s disease, therapy, nanomedicine, nanoparticles, nutraceutical, intranasal route, green synthesis, stem cells |
|---|